麻豆传媒

The FDA expanded the indications for the immune checkpoint inhibitor durvalumab (Imfinzi) to include limited-stage small cell lung cancer (SCLC).

stipulates use of the PD-L1 inhibitor in limited-stage SCLC that has not progressed following platinum-based concurrent chemoradiation.

Support for the approval came from the phase III ADRIATIC trial of 730 patients with stage I-III SCLC, all of whom had non-progressive disease following standard-of-care platinum-based chemoradiation. Patients were randomized to placebo or to durvalumab with or without the CTLA-4 inhibitor tremelimumab (Imjudo). The , leaving 536 patients for the analysis of durvalumab versus placebo.

The results showed an unprecedented improvement in median overall survival of almost 2 years, from 33.4 months with placebo to 55.9 months with durvalumab (HR 0.73, 95% CI 0.57-0.93). Median progression-free survival improved from 9.2 months with placebo to 16.6 months with the anti-PD-L1 monoclonal antibody (HR 0.76, 95% CI 0.61-0.95).

"Consolidation durvalumab will become the new standard of care for patients with limited-stage small cell lung cancer following chemoradiotherapy," said David Spigel, MD, of Sarah Cannon Research Institute in Nashville, Tennessee, during a presentation at the American Society of Clinical Oncology (ASCO) meeting earlier this year.

ASCO-invited discussant Lauren Byers, MD, of the University of Texas MD Anderson Cancer Center in Houston, said ADRIATIC is a "landmark study and provides a new standard of care for patients with early-stage small cell lung cancer."

Grade 3/4 adverse events occurred in 24% of patients treated with durvalumab or placebo. The most common all-grade AEs (≥20% of patients) were pneumonitis/radiation pneumonitis, which reached grade 3/4 severity in 3.1% of durvalumab-treated patients and 2.6% of the placebo group.

Comment